4basebio plc (4BB) ORD EUR1
4basebio PLC is a United Kingdom-based specialist life sciences company. The Company is engaged in developing next generation gene therapy technologies and solutions. The Company is focused on supplying therapeutic deoxyribonucleic (DNA) for gene therapies and DNA vaccines and also for providing solutions for delivery of the DNA based products to patients. The Company focuses to manufacture and supply synthetic DNA for research, therapeutic and pharmacological use. Its TruePrime DNA amplification technology is a primer free DNA amplification method using enzymes. Its Hermes is a non-viral delivery platform that can be used to deliver various payloads, ranging from DNA to small interfering ribonucleic acid (siRNA), as well as protein cargoes. It also offers a messenger ribonucleic acid (mRNA) production service from the DNA template it makes. It offers a range of services including production of synthetic DNA and RNA payloads, design and assembly of payloads in nanoparticles.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.